5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Daptomycin has concentration-dependent antibacterial activity against Gram-positive bacteria. Its use is increasing in haemodialysis units. The manufacturer recommends a 4-6-mg/kg dose administered every 48 hrs for patients receiving haemodialysis. However, there are no published data about daptomycin pharmacokinetics and clearance during haemodialysis. The recommended dosing regimen would conflict with asymmetric thrice-weekly haemodialysis, which yields two ~44-hr and one ~68-hr interdialytic periods. This is the first study to evaluate daptomycin pharmacokinetics in haemodialysis patients, assess the extent of daptomycin dialytic removal and model serum concentrations at 44 and 68 hrs.

          Related collections

          Author and article information

          Journal
          Nephrol. Dial. Transplant.
          Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
          Oxford University Press (OUP)
          1460-2385
          0931-0509
          Apr 2010
          : 25
          : 4
          Affiliations
          [1 ] University of Michigan College of Pharmacy, Department of Clinical, Social & Administrative Sciences, Ann Arbor, MI, USA.
          Article
          gfp655
          10.1093/ndt/gfp655
          2902860
          20007981

          Comments

          Comment on this article